Andersen-Tawil syndrome tertiary prevention

Andersen-Tawil syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Andersen-Tawil syndrome from other Diseases
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Tertiary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Andersen-Tawil syndrome tertiary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
slides
Images
American Roentgen Ray Society Images of Andersen-Tawil syndrome tertiary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Andersen-Tawil syndrome tertiary prevention
CDC on Andersen-Tawil syndrome tertiary prevention
Andersen-Tawil syndrome tertiary prevention in the news
Blogs on Andersen-Tawil syndrome tertiary prevention
Directions to Hospitals Treating Andersen-Tawil syndrome
Risk calculators and risk factors for Andersen-Tawil syndrome tertiary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2]; Raviteja Guddeti, M.B.B.S. [3]

Tertiary Prevention

The following precautions should be taken to prevent complications in a patient with Andersen-Tawil syndrome:

• Caution while prescribing certain antiarrhythmics such as those belonging to class I as they may paradoxically exacerbate the neuromuscular symptoms.
• Caution should be maintained while administering anesthesia to these patients to prevent malignant hyperthermia.

References

Template:WikiDoc Sources CME Category::Cardiology